| Subject: | FDA Approves Safety Labeling Changes to Commonly Used Drugs |
| Category: | Food and Drug Administration (FDA)
|
| Published: | Wed, 31 Aug 2005 - 10:00 am |
| The FDA has approved safety-labeling changes to commonly used medications. Changes have been made to the CONTRAINDICATIONS, BOXED WARNING, WARNINGS, PRECAUTIONS, or ADVERSE REACTIONS. For detailed information on individual drugs, click on the links or documents below.
3% and 5% Sodium Chloride Injection, USP -5% Dextrose and Electrolyte No. 48 Injection -5% Dextrose and Electrolyte No. 75 Injection -Accolate (zafirlukast) Tablets -Activella (estradiol/norethindrone acetate... The full article is available to StayAlert subscribers. Click here for a free trial subscription. |
|
RESOURCES:
Customizable Documents and Tools:
External Links:
Related MCN Products:
|
|
With over 20 years experience in regulatory compliance, MCN Healthcare brings you the most comprehensive regulatory compliance tool available. StayAlert! is the only comprehensive e-mail notification service available that not only notifies you of the changes in major federal regulations, but also provides the policies, procedures, tools and best practices to help you meet the changing regulation. StayAlert! actively monitors TJC (JCAHO), CDC, CMS, DHHS, FDA, OSHA, OIG and many others so you don't have to. Currently StayAlert! is the leader in the comprehensive compliance information marketplace. Why? Because StayAlert! provides healthcare professionals with more than information. StayAlert! provides a service, in many cases "doing the work" for you, and assisting regulatory compliance officers to effectively and efficiently meet changing standards. |
|
